COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Evaluate Safety, Efficacy and Pharmacokinetics (Compare)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01084863
Recruitment Status : Active, not recruiting
First Posted : March 11, 2010
Last Update Posted : August 9, 2019
Information provided by (Responsible Party):

Brief Summary:
The purpose of the study is to demonstrate equivalent pharmacokinetics (PK)

Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Drug: CT-P6 Drug: Herceptin Drug: Paclitaxel Phase 1 Phase 2

Detailed Description:
Patients will receive CT-P6 or Herceptin.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 174 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Double-blind Randomised Phase I/IIb Study
Actual Study Start Date : February 2010
Actual Primary Completion Date : December 2011
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: CT-P6 & Paclitaxel
CT-P6 + Paclitaxel
Drug: CT-P6
CT-P6: administered every 3 weeks

Drug: Paclitaxel
Paclitaxel: administered every 3 weeks

Active Comparator: Herceptin & Paclitaxel
Trastuzumab + Paclitaxel
Drug: Herceptin
Herceptin: administered every 3 weeks
Other Name: Trastuzumab

Drug: Paclitaxel
Paclitaxel: administered every 3 weeks

Primary Outcome Measures :
  1. PK parameter [ Time Frame: months ]

Secondary Outcome Measures :
  1. PK data, safety and efficacy [ Time Frame: months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Are females
  • Have a Her 2 over-expression
  • Have ECOG 0 or 1

Exclusion Criteria:

  • Current clinical or radiographic evidence CNS metastases
  • Current Known infection
  • Pregnant or nursing mother

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01084863

Layout table for location information
Korea, Republic of
Samsung Medical Center
Seoul, Korea, Republic of
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Investigational Site Samsung Medical Center
Layout table for additonal information
Responsible Party: Celltrion Identifier: NCT01084863    
Other Study ID Numbers: CT-P6/1.1
First Posted: March 11, 2010    Key Record Dates
Last Update Posted: August 9, 2019
Last Verified: August 2019
Keywords provided by Celltrion:
Her 2-positive
metastatic breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological